Catabasis Pharmaceuticals (NASDAQ:ATXS) Given Buy Rating at HC Wainwright

Catabasis Pharmaceuticals (NASDAQ:ATXS – Get Rating)‘s stock had its “buy” rating reiterated by HC Wainwright in a research report issued to clients and investors on Friday, TipRanks reports. They presently have a $13.00 price objective on the biotechnology company’s stock. HC Wainwright’s price target suggests a potential upside of 83.10% from the stock’s current price. […]

Related Keywords

Boston ,Massachusetts ,United States ,Blackrock ,Jillc Milne ,Michaelr Jirousek ,Stevene Shoelson , ,Northern Trust Corp ,Geode Capital Management ,Analyst Recommendations For Catabasis Pharmaceuticals ,Zacks Investment Research ,Catabasis Pharmaceuticals Get Rating ,Astria Therapeutics Inc ,Blackrock Inc ,Oppenheimer Co ,Catabasis Pharmaceuticals ,Millennium Management ,Get Rating ,Capital Management ,Trust Corp ,Nasdaq Atxs ,Atxs ,Medical ,Reiterated Rating ,Hc Wainwright ,